Labcorp Holdings Inc Stock Price, News & Analysis

Labcorp (NYSE: LH) announces that Dr. Marcia Eisenberg, chief scientific officer, has been honored as a 2021 Luminary by the Healthcare Businesswomen’s Association (HBA). Dr. Eisenberg's recognition celebrates over 30 years of contributions to healthcare innovation and her support for women in STEM. She has played a pivotal role in the commercialization of PCR testing and COVID-19 diagnostics. The honor will be conferred during the virtual Woman of the Year event on May 6. Labcorp reported $14.0 billion in revenue for FY2020.

Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at KeyBanc Capital Markets' Life Sciences and MedTech Investor Forum on March 24 at 2:00 p.m. ET. A live webcast of the presentation will be available on the company's website and archived for later viewing.

Labcorp is a global life sciences leader, providing essential diagnostic and drug development services. The company reported revenue of $14 billion in FY2020 and serves clients in over 100 countries.

Labcorp (NYSE: LH) and PathAI have expanded their strategic partnership focusing on AI-powered pathology. This collaboration will enable seamless deployment of PathAI algorithms in clinical trials managed by Labcorp. Key objectives include enhancing patient stratification and developing companion diagnostic devices using robust AI-driven analytics. Labcorp aims to leverage this collaboration to advance drug development and improve patient outcomes, reflecting significant developments in digital pathology.

Walgreens has partnered with Labcorp to sell the Pixel by Labcorp COVID-19 PCR Test Home Collection Kits over-the-counter at 6,000 stores nationwide. Starting spring 2021, this will be Walgreens' first in-store testing option, enhancing access in underserved areas. Walgreens aims to increase its on-site testing capacity to over 5,000 locations by April 1. The kits allow customers to self-administer tests and send samples to Labcorp for processing. Test results will be available online, with follow-up by healthcare professionals for positive results.

Labcorp (NYSE: LH) announced that its executive management team will participate in a virtual fireside chat at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 25 at 1:30 p.m. ET. A live webcast of the event will be available on the company's website and archived for later replay.

As a leading global life sciences company, Labcorp reported $14 billion in revenue for FY2020 and employs over 75,000 people serving clients in more than 100 countries, providing vital insights and innovations to improve health.

Labcorp (NYSE: LH) has launched a new laboratory-based antigen test to help determine active COVID-19 infections. Developed by DiaSorin, this test requires a doctor's order and is conducted using a nasal or nasopharyngeal swab. Results are typically available within 24-48 hours. Labcorp emphasizes that while PCR tests remain the gold standard for COVID-19 diagnosis, antigen tests are an important tool for assessing infection status. The test has been made available in the U.S. following FDA notification on October 26, 2020.

Labcorp (NYSE: LH) announced that its CMO, Amy Summy, was named on the 2021 Forbes CMO Next list for her leadership during the COVID-19 pandemic. Her contributions include spearheading a successful rebranding strategy and launching the Pixel by Labcorp™ at-home testing kits. Recognized for innovation and impact in healthcare, Summy emphasized the role of Labcorp employees in fighting COVID-19. The company reported a revenue of $14 billion in FY2020 and aims to improve patient outcomes across various diseases.

Labcorp (NYSE: LH) reported a strong performance for Q4 and full year 2020, with revenues of $4.49 billion in Q4, a 52% increase year-over-year, driven by COVID-19 testing and a growing base diagnostics business. Net earnings rose to $938.3 million, or $9.54 per diluted share. For 2021, the company projects revenue growth of 1% to 4% and expects a 50% decline in COVID-19 testing revenues. Labcorp emphasized its commitment to science and innovation and anticipates free cash flow between $1.70 billion and $1.90 billion.